Nabriva therapeutics appoints CEO
This article was originally published in Scrip
Executive Summary
Biotechnology company Nabriva Therapeutics, which is developing a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, has named Dr Colin Broom chief executive officer. Prior to joining Vienna-based Nabriva Dr Broom was chief scientific officer at ViroPharma, which was acquired by Shire in January 2014. He succeeds Ralf Schmid, who will remain at the company as a member of the executive management team and will move to the role of chief financial officer and chief operating officer.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.